MARKET

SAVA

SAVA

Cassava Sciences
NASDAQ
20.62
+0.12
+0.59%
Opening 15:45 04/23 EDT
OPEN
20.65
PREV CLOSE
20.50
HIGH
21.21
LOW
20.35
VOLUME
417.54K
TURNOVER
0
52 WEEK HIGH
32.10
52 WEEK LOW
12.32
MARKET CAP
891.73M
P/E (TTM)
-8.8941
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SAVA last week (0415-0419)?
Weekly Report · 1d ago
Noteworthy Tuesday Option Activity: BX, WBD, SAVA
NASDAQ · 04/16 19:26
Weekly Report: what happened at SAVA last week (0408-0412)?
Weekly Report · 04/15 10:34
Redemption Date Announced for Warrants
Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to shareholders on January 3, 2024. Holders who exercise their warrants will receive 1.5 shares of Cassava Sciences’ common stock per Warrant, for an effective price of approximately $22.00.
Barchart · 04/15 08:20
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
JPMorgan Chase & Co. Shares dipped 5.1% to $185.49 following first-quarter earnings on Friday. PaxMedica, Inc. Shares jumped 143% after the company reported better-than-expected results on Thursday. Rent the Runway shares jumped 162% on Thursday after reporting mixed results.
Benzinga · 04/12 18:47
Analysts’ Top Healthcare Picks: Mainz Biomed B.V. (MYNZ), Century Therapeutics (IPSC)
TipRanks · 04/12 10:20
Weekly Report: what happened at SAVA last week (0401-0405)?
Weekly Report · 04/08 10:38
Weekly Report: what happened at SAVA last week (0325-0329)?
Weekly Report · 04/01 10:37
More
About SAVA
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.

Webull offers Cassava Sciences Inc stock information, including NASDAQ: SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.